{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:59:17Z","timestamp":1790629157713,"version":"4.1.0"},"reference-count":9,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interact J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Natural health product (NHP) regulations have shifted in Canada, with the aim of reducing \u201cred tape\u201d and enabling market entry. This study assessed how many \u201cstem cell\u201d supplements for sale on Amazon.ca had Health Canada\u2013required natural product number (NPN) licenses compared with vitamin D and \u201clongevity\u201d supplements. It also conducted a marketing overview analysis comparing the Amazon.ca discourse across the 3 product types. Findings show a gap in regulatory licensing compliance between \u201cstem cell\u201d supplements and vitamin D or \u201clongevity\u201d supplements. Marketing discourse also presented potential conflict with regulatory parameters. We discuss the impacts of loosening NHP regulations and the potential for products with weak evidentiary bases to enhance validation through NPN licensing.<\/jats:p>","DOI":"10.2196\/86747","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:10:05Z","timestamp":1790626205000},"page":"e86747-e86747","source":"Crossref","is-referenced-by-count":0,"title":["The Shifting Landscape of Natural Health Product Licensing in Canada: The e-Commerce Case of Stem Cell Supplements"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-423X","authenticated-orcid":false,"given":"Alessandro R","family":"Marcon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2128-1883","authenticated-orcid":false,"given":"Michael","family":"Jewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5471-6184","authenticated-orcid":false,"given":"Timothy","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"4","key":"R1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcyt.2024.01.001","article-title":"US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration\u2019s enforcement discretion era","volume":"26","author":"Turner","journal-title":"Cytotherapy"},{"issue":"11","key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102675","article-title":"The marketing of \u201cstem cell\u201d supplements on Amazon.com: Assessing alignment with regulatory frameworks in the United States and Canada","volume":"20","author":"Marcon","journal-title":"Stem Cell Reports"},{"key":"R3","unstructured":"Natural health product regulation in Canada: overview. Government of Canada. 2026. URL: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/natural-non-prescription\/regulation.html [Accessed 14-09-2026]"},{"key":"R4","unstructured":"Public Health Agency of CanadaHealth Canada. Health Canada and the Public Health Agency of Canada\u2019s report on red tape reduction. Government of Canada; 2025. URL: https:\/\/www.canada.ca\/en\/services\/health\/publications\/health-system-services\/report-red-tape-reduction.html#a6 [Accessed 18-09-2026]"},{"key":"R5","unstructured":"Health Canada. Search licensed natural health products. Government of Canada. 2024. URL: https:\/\/health-products.canada.ca\/lnhpd-bdpsnh\/?lang=eng [Accessed 18-09-2026]"},{"key":"R6","unstructured":"Health Canada. Guidance document: Schedule A and Section 3 of the Food and Drugs Act. Government of Canada; 2003. URL: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/guidance-document-schedule-section-3-food-drugs-act.html [Accessed 18-09-2026]"},{"issue":"12","key":"R7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1093\/gerona\/glad106","article-title":"Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions","volume":"78","author":"Freeberg","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41574-021-00593-z","article-title":"The health effects of vitamin D supplementation: evidence from human studies","volume":"18","author":"Bouillon","journal-title":"Nat Rev Endocrinol"},{"key":"R9","unstructured":"Marcon AR . Supplements for sale on Amazon.ca (June 27, 2026). OSF. URL: https:\/\/osf.io\/ka6z8\/overview [Accessed 18-09-2026]"}],"container-title":["Interactive Journal of Medical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:10:08Z","timestamp":1790626208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.i-jmr.org\/2026\/1\/e86747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":9,"URL":"https:\/\/doi.org\/10.2196\/86747","relation":{},"ISSN":["1929-073X"],"issn-type":[{"value":"1929-073X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"v15i4e86747"}}